Charles Schwab Investment Management Inc. Invests $55,000 in Neuronetics, Inc. $STIM

Charles Schwab Investment Management Inc. acquired a new position in shares of Neuronetics, Inc. (NASDAQ:STIM) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 15,000 shares of the company’s stock, valued at approximately $55,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Balyasny Asset Management L.P. lifted its stake in shares of Neuronetics by 29.5% during the fourth quarter. Balyasny Asset Management L.P. now owns 1,481,771 shares of the company’s stock worth $2,386,000 after buying an additional 337,539 shares during the period. Nkcfo LLC acquired a new stake in Neuronetics during the 1st quarter valued at approximately $460,000. Assenagon Asset Management S.A. acquired a new stake in Neuronetics during the 1st quarter valued at approximately $359,000. Citizens Financial Group Inc. RI acquired a new stake in Neuronetics during the 1st quarter valued at approximately $305,000. Finally, Tradewinds LLC. lifted its stake in Neuronetics by 264.9% during the 1st quarter. Tradewinds LLC. now owns 72,977 shares of the company’s stock valued at $269,000 after acquiring an additional 52,977 shares during the period. 53.59% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group decreased their price objective on shares of Neuronetics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $7.00.

Neuronetics Trading Up 1.2%

Shares of Neuronetics stock opened at $3.31 on Friday. The firm has a 50-day simple moving average of $3.75 and a two-hundred day simple moving average of $4.00. The company has a market cap of $218.86 million, a P/E ratio of -2.93 and a beta of 1.28. Neuronetics, Inc. has a fifty-two week low of $0.52 and a fifty-two week high of $5.92. The company has a debt-to-equity ratio of 1.76, a quick ratio of 1.84 and a current ratio of 2.02.

Neuronetics (NASDAQ:STIM) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.07). The company had revenue of $38.11 million during the quarter, compared to analysts’ expectations of $36.80 million. Neuronetics had a negative return on equity of 156.36% and a negative net margin of 43.47%. Neuronetics has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities analysts predict that Neuronetics, Inc. will post -1.13 earnings per share for the current fiscal year.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.